EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:ACAD

ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

$14.67
-0.10 (-0.68%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$14.56
$14.92
50-Day Range
$14.49
$18.63
52-Week Range
$12.24
$28.06
Volume
1.14 million shs
Average Volume
1.82 million shs
Market Capitalization
$2.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.47

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.42 Rating Score
Upside/​Downside
46.4% Upside
$21.47 Price Target
Short Interest
Healthy
5.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$93,130 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.32) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

117th out of 1,038 stocks

Pharmaceutical Preparations Industry

42nd out of 510 stocks

ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

RBC Capital Keeps Their Buy Rating on Spruce Biosciences (SPRB)
ACADIA Pharmaceuticals Inc
Tracking Baker Brothers Portfolio - Q2 2022 Update
ACAD ACADIA Pharmaceuticals Inc.
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
11/02/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.47
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+46.4%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
19 Analysts

Profitability

Net Income
$-167,870,000.00
Pretax Margin
-42.12%

Debt

Sales & Book Value

Annual Sales
$484.14 million
Book Value
$3.36 per share

Miscellaneous

Free Float
115,943,000
Market Cap
$2.38 billion
Optionable
Optionable
Beta
0.60

Key Executives

  • Mr. Stephen R. Davis J.D.Mr. Stephen R. Davis J.D. (Age 61)
    CEO & Director
    Comp: $1.03M
  • Dr. Srdjan R. Stankovic M.D.Dr. Srdjan R. Stankovic M.D. (Age 65)
    M.S.P.H., Pres
    Comp: $933.1k
  • Mr. Mark C. Schneyer (Age 48)
    Exec. VP & CFO
    Comp: $555.49k
  • Mr. Brendan P. TeehanMr. Brendan P. Teehan (Age 53)
    Exec. VP, COO & Head of Commercial
    Comp: $486.47k
  • Mr. Austin D. KimMr. Austin D. Kim (Age 58)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $559.24k
  • Mr. James K. KiharaMr. James K. Kihara (Age 41)
    VP, Chief Accounting Officer & Corp. Controller
  • Mr. Bob Mischler
    Sr. VP of Strategy & Technology Operations
  • Mr. Mark C. Johnson
    VP of Investor Relations
  • Ms. Julie Fisher
    Sr. VP of Marketing & Commercial Strategy
  • Ms. Holly Valdiviez
    Sr. VP & Head of Sales













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

19 equities research analysts have issued 12 month target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they expect the company's stock price to reach $21.47 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2022?

ACADIA Pharmaceuticals' stock was trading at $23.34 at the beginning of 2022. Since then, ACAD stock has decreased by 37.4% and is now trading at $14.61.
View the best growth stocks for 2022 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 9,040,000 shares, a drop of 13.4% from the October 31st total of 10,440,000 shares. Based on an average trading volume of 1,450,000 shares, the short-interest ratio is presently 6.2 days. Approximately 5.7% of the shares of the stock are sold short.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Wednesday, November, 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. The biopharmaceutical company earned $130.70 million during the quarter, compared to the consensus estimate of $139.04 million. ACADIA Pharmaceuticals had a negative net margin of 42.49% and a negative trailing twelve-month return on equity of 47.09%. ACADIA Pharmaceuticals's revenue for the quarter was down .7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.09) earnings per share.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $510.00 million-$520.00 million, compared to the consensus revenue estimate of $530.69 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.98%), BlackRock Inc. (6.16%), State Street Corp (4.19%), Price T Rowe Associates Inc. MD (3.02%), RTW Investments LP (2.27%) and First Trust Advisors LP (1.80%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $14.61.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $2.37 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 11/29/2022 by MarketBeat.com Staff